Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 17/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 17/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442756 | 0.80 | MEN1 (0.51) | TAS1R3TAS1R1MEN1KMT2ATDP1 | |
| SCHEMBL1634494 | 0.75 | MEN1 (0.44) | TAS1R3TAS1R1MEN1KMT2ATDP1 | |
| SCHEMBL4828073 | 0.74 | MEN1 (0.53) | MEN1KMT2ATDP1 | |
| SCHEMBL22060698 | 0.72 | TAS1R3 (0.58) | TAS1R3TAS1R1MEN1KMT2A | |
| SCHEMBL13169591 | 0.72 | TAS1R3 (0.70) | TAS1R3TAS1R1DRD2 | |
| SCHEMBL1636418 | 0.71 | MEN1 (0.47) | TAS1R3TAS1R1MEN1KMT2ATDP1 | |
| SCHEMBL5657142 | 0.71 | MEN1 (0.43) | MEN1KMT2ATDP1 | |
| SCHEMBL1636233 | 0.71 | MEN1 (0.47) | TAS1R3TAS1R1MEN1KMT2ATDP1 | |
| SCHEMBL11918676 | 0.71 | TAS1R3 (0.71) | TAS1R3TAS1R1DRD2 | |
| SCHEMBL15271619 | 0.70 | MEN1 (0.51) | TAS1R3TAS1R1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932266-B2 | Ester or amide derived from (3-sec-butyl-1-(thio)oxo-2,3-dihydro-1H-isoquinolin-4-yliden)-acetic acid; neurodegenerative diseases, cerebral and cardiac ischemias | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2011-04-26 | — | — | US | claimed |
| US-20080090862-A1 | Isoquinoline Derivatives as Calpain Inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2008-04-17 | — | — | US | claimed |
| EP-1829864-A1 | ISOQUINOLINE DERIVATIVES AS CALPAIN INHIBITORS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2007-09-05 | — | — | EP | claimed |
| US-7932266-B2 | Ester or amide derived from (3-sec-butyl-1-(thio)oxo-2,3-dihydro-1H-isoquinolin-4-yliden)-acetic acid; neurodegenerative diseases, cerebral and cardiac ischemias | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2011-04-26 | — | — | US | disclosed |
| US-20080090862-A1 | Isoquinoline Derivatives as Calpain Inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2008-04-17 | — | — | US | disclosed |
| CN-101128433-A | Isoquinoline derivatives as calpain inhibitors | CONSEJO SUPERIOR INVESTIGACION (ES) | 2008-02-20 | — | — | CN | disclosed |
| EP-1829864-A1 | ISOQUINOLINE DERIVATIVES AS CALPAIN INHIBITORS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090862-A1 | Isoquinoline Derivatives as Calpain Inhibitors | CAPN1, CAPN2, CAPNS1 | TAS1R3 4133/4885TAS1R1 4270/4885DRD2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.